

ReiThera to Present Five Posters and Introduce New U.S. Business Development Lead at ASGCT 2025

Rome, Italy - May 12 2025 – ReiThera, the Italian CDMO company specialized in the development and manufacturing of genetic vaccines and advanced therapies, is pleased to announce its participation in the 27th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT), taking place May 13–17, 2025, in New Orleans, LA.

ReiThera will be exhibiting at booth #545, where attendees can explore the company's end-to-end solutions for scalable viral vector production and its growing portfolio of technology platforms supporting gene and cell therapy development.

The company is proud to have five scientific posters accepted for display during the congress. These posters reflect ReiThera's continued efforts in process innovation and industrialization of advanced therapy products. Among them, a standout contribution titled **'ReiCell-AAV: A Fully Documented High-Yield Suspension Cell Line for Scalable AAV Vector Manufacturing'** illustrates ReiThera's new cell-line and its advancements in upstream development to support efficient and robust AAV vector production.

ASGCT 2025 also marks an opportunity to strengthen connections with ReiThera's partners and collaborators from all around the world. The company is pleased to announce that Thomas De Maria has joined as Head of Business Development, US. Based in the United States and bringing a strong background in gene therapy manufacturing and strategic partnerships, Thomas will be present at the meeting to engage with attendees and introduce ReiThera's capabilities to a broader network.

Although he will not be attending the event in person, ReiThera's CEO, Dr. Stefano Colloca, expressed strong confidence in the team representing the company:

"ASGCT is a key moment for our field, and while this is an extremely intense period for ReiThera due to major ongoing projects, I am proud of the outstanding team that will be on site. Their expertise and dedication reflect the values and vision that drive our company forward."

ReiThera's presence at ASGCT highlights its dedication to supporting the gene therapy community with reliable, scalable, and innovative manufacturing solutions.

To connect with the ReiThera team during the conference or to learn more about our work, please contact the team at businessdevelopment@reithera.com.

About ReiThera:

ReiThera Srl is a CDMO specialized in the development of scalable processes and GMP manufacturing of viral vectors for gene therapies, genetic vaccines, and advanced medicinal products. With extensive expertise in viral vector production—including Adeno-Associated Virus (AAV), Lentivirus, Adenoviral Vector (AdV), Modified Vaccinia Ankara (MVA), and Herpes Simplex Vector—ReiThera supports the clinical translation of innovative therapies. The company operates a state-of-the-art facility in Rome, Italy, equipped with stirred-tank bioreactors ranging from 50L to 2000L, fixed-bed bioreactors for adherent cell growth, a filling suite, and advanced quality control laboratories. ReiThera's manufacturing capabilities cover both small- and large-scale production, ensuring rapid transitions from laboratory to clinical and commercial GMP-grade material, with production volumes of up to 3000L.

ReiThera has demonstrated its ability to respond quickly to global health challenges through collaborations with research institutes, pharmaceutical companies, and international partners, solidifying its position as a leading Italian company in the biotechnology sector. For more information, visit www.reithera.com.